In the article “Gadolinium Deposition Disease: A New Risk Management Threat,” Harvey et al [ 1 Harvey H.B. Gowda V. Cheng G. Gadolinium deposition disease: a new risk management threat. J Am Coll Radiol. 2020; 17: 546-550 Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar ] present their opinion regarding management of risk associated with gadolinium deposition disease (GDD). Basing their assessment on their interpretation of published data, legal precedent, and their understanding of American jurisprudence and regulatory environment, the take-home points of the article include: ▪There have been numerous lawsuits filed regarding GDD. ▪The authors are concerned that such lawsuits may increase in the future. ▪Because the signs and symptoms that have been proposed to comprise GDD are supposedly related to gadolinium retention in the first 2 months after gadolinium-based contrast agent (GBCA) administration, they advise using gadoteridol, which is a GBCA that they feel has been associated with the least amount of gadolinium deposition in the brain. They recommend reserving other GBCAs for use “only when clinically advisable.” Despite the lack of evidence that gadolinium retention results in any harmful clinical manifestations, they recommend that usage of this agent will decrease radiologists’ potential legal exposure.